ENGLEWOOD, CO / ACCESSWIRE / May 3, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU) (the "Company"), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has been featured in a local ABC News segment presented by medical specialist anchor Kristi Krueger: "UM doctors test new medication for treating men with low testosterone. Nasal testosterone gel doesn't appear to have negative side effects, doctors say."

To view the segment in its entirety and to read the article, please visit the link below:


The video segment and news article notes:

'Doctors say there are two major side effects [to testosterone replacement therapy]. "One, it blocks the sperm production, especially for young men or men who wish to conceive in the future and are still interested in fertility and family building," said Dr. Ranjith Ramasamy, director of reproductive urology at the University of Miami Health System.' 'Ramasamy said testosterone therapy also blocks any natural testosterone production. "[For young married men], you want to keep your options open (and) don't want to close off any avenues with your wife and your ability to have kids or not," he said.

But doctors are now studying a medication called Natesto, a nasal testosterone gel that does not appear to have the negative side effects.'

'The University of Miami Health System is the only location in the country studying Natesto. So far, 12 men have participated in the study and doctors say all of them have had promising results.

"We have so far found all the men on the nasal gel therapy for at least three months, they are very happy, testosterone levels have improved, and their sperm production is maintained," Ramasamy said.'

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS® is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within growing markets. For more information, visit www.aytubio.com.

Aytu also now wholly-owns its subsidiary Aytu Women's Health (formerly Nuelle, Inc.), a personal health and wellness company focused on women's sexual wellbeing and intimacy. Aytu Women's Health markets Fiera, a personal care product for women that is scientifically proven to enhance physical arousal and sexual desire. Fiera is a consumer product and is not intended to treat, mitigate, or cure any disease or medical condition. For more information about the Fiera personal care product visit www.fiera.com.

For more information:

James Carbonara
Hayden IR

SOURCE: Aytu BioScience, Inc.